NewcelX management attends Breakthrough T1D Clinical & Research Congress
NCEL•NewcelX management plans to attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on Oct. 9-11, 2026, and meet with researchers, clinicians, investors and strategic partners about NCEL-101 ahead of a planned Phase 1/2a trial.
1. Congress meetings planned
NewcelX management plans to attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on Oct. 9-11, 2026. Meetings with researchers, clinicians, investors and strategic partners are planned to discuss NCEL-101 ahead of a planned Phase 1/2a trial in Type 1 diabetes.
2. FDA meeting preceded congress
The planned engagement follows a Type B pre-IND meeting with the FDA that aligned on a development strategy for NCEL-101.
